Leucine zipper protein 2 serves as a prognostic biomarker for prostate cancer correlating with immune infiltration and epigenetic regulation

BACKGROUND: We sought to determine whether leucine zipper protein 2 (LUZP2) could benefit men with prostate cancer (PCa) undergoing radical radiotherapy (RT) or prostatectomy (RP). METHODS: Analysis was done on differentiating expression, clinical prognosis, co-expressed genes, immune infiltration,...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Dechao, Zhu, Weizhen, Shi, Xu, Wei, Wuran, Han, Ping, Wei, Qiang, Yang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547219/
https://www.ncbi.nlm.nih.gov/pubmed/36217461
http://dx.doi.org/10.1016/j.heliyon.2022.e10750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547219/
https://www.ncbi.nlm.nih.gov/pubmed/36217461
http://dx.doi.org/10.1016/j.heliyon.2022.e10750

Ejemplares similares